A Russian research facility has announced the upcoming initiation of clinical trials for a novel, personalized cancer vaccine developed using advanced mRNA technology. The initial phase will target patients with melanoma and will be conducted in partnership with Moscow's Hertsen Research Institute and Blokhin Cancer Center. While the Gamaleya Center will oversee vaccine manufacturing, the clinical studies will be coordinated by these prominent oncology centers.
Since mid-2022, scientists have been working on this innovative vaccine that employs artificial intelligence to customize treatment based on individual genetic and tumor profiles. This personalized approach enables the vaccine to train the immune system to specifically target and eliminate tumor cells through cytotoxic lymphocytes. The process from tumor analysis to vaccine formulation can be completed within approximately one week, thanks to AI integration.
Preliminary results from animal testing and limited human trials have been promising. Although the initial focus is on melanoma, researchers are also developing vaccine models for other cancers, including pancreatic, kidney, and non-small-cell lung cancer, which is amo...
Russia Prepares to Launch Personalized mRNA Cancer Vaccine Trials
News Site